ERBB2 and cancer: Although there are several clinical trials of drugs targeting ERBB2-mutant tumors with accumulating data, research on targeting ERBB2 mutations for cancer treatment has been slow owing to their low mutation frequency, insufficient understanding of their biological activity, and difficulty in detection [11].